154 related articles for article (PubMed ID: 1926644)
1. Use of biological response modifiers for management of renal cell carcinoma.
Wilkinson M; Aronson F
Urol Int; 1991; 46(3):304-8. PubMed ID: 1926644
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
[No Abstract] [Full Text] [Related]
3. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
Ueno NT; Zukiwski AA
Am J Clin Oncol; 1995 Aug; 18(4):358-62. PubMed ID: 7625380
[No Abstract] [Full Text] [Related]
4. Immunotherapy of renal cell carcinoma.
Haas GP; Hillman GG; Redman BG; Pontes JE
CA Cancer J Clin; 1993; 43(3):177-87. PubMed ID: 8490757
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
6. European studies of interleukin-2 in metastatic renal cell carcinoma.
Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
[No Abstract] [Full Text] [Related]
7. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
8. Role of interferons in the therapy of metastatic renal cell carcinoma.
Quesada JR
Urology; 1989 Oct; 34(4 Suppl):80-3; discussion 87-96. PubMed ID: 2678687
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?
Young RC
N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587
[No Abstract] [Full Text] [Related]
10. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
[TBL] [Abstract][Full Text] [Related]
11. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
12. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
13. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced renal cancer.
Atkins MB
Kidney Int; 2005 May; 67(5):2069-82. PubMed ID: 15840065
[No Abstract] [Full Text] [Related]
16. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
17. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
18. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
19. [Phase II trial of treatment of metastatic renal adenocarcinoma with recombinant leukocyte interferon (rDNA IFN-alpha 2)].
Dorval T; Palangie T; Garcia-Giralt E; Jouve M; Bretaudeau B; Falcoff F; Coninx P; Schwab D; Pouillart P
Bull Cancer; 1985; 72(5):470-1. PubMed ID: 4074917
[No Abstract] [Full Text] [Related]
20. [Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies].
Otto U; Schneider A; Denkhaus H; Conrad S
Onkologie; 1988 Aug; 11(4):185-91. PubMed ID: 3141856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]